TABLE 1.
Clinical and Demographic Characteristics of the STN-DBS Participants
| ID | Age (yr) |
Education (yr) |
PD (yr) |
DBS (mo) |
Levodopa (mg/day) |
UPDRSIII OFF |
UPDRS III ON |
|---|---|---|---|---|---|---|---|
| 103 | 54 | 14 | 14 | 44 | 250 | 51.0 | 25.0 |
| 104 | 57 | 16 | 16 | 27 | 400 | 57.0 | 55.5 |
| 106 | 59 | 15 | 10 | 09 | 600 | 27.5 | 19.0 |
| 107 | 62 | 18 | 15 | 02 | 600 | 26.0 | 23.0 |
| 109 | 49 | 16 | 09 | 04 | 300 | 23.5 | 21.5 |
| 110 | 62 | 11 | 11 | 56 | 600 | 52.5 | 31.0 |
| 111 | 56 | 11 | 11 | 37 | 400 | 11.5 | 4.0 |
| Mean | 57 | 14.4 | 12.3 | 25.6 | 450 | 35.6 | 25.6 |
All subjects were right-handed males and all but one subject were native speakers of English (106 was a native speaker of Italian who immigrated to the US as an adolescent). Age, education, and the duration of PD (PD) are in years. The duration of STN-DBS (DBS) is in months. Levodopa refers to the daily dose in mg. The Unified Parkinson’s Disease Rating Scale III (motor ratings) (UPDRS; Fahn et al., 1987) are off-medication and with STN-DBS on and off. Subject 104 had maximum scores on the rigidity items on the UPDRS III, which were not responsive to STN-DBS.